Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reeling From Lehman Bros-linked Loss, China’s 3SBio Aims To Bioengineer Its Own Recovery

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Stung by a loss of nearly $3 million in late 2008 tied to the U.S. financial meltdown, leading Chinese biopharmaceutical outfit 3SBio is laying the drug development groundwork for a profit rebound this year and next

You may also be interested in...



3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO

SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China

3SBio Sees Strong Growth In Q1 Driven By Oncology Product EPIAO

SHANGHAI - Biotech company 3SBio saw revenues increase 23.7 percent in the first quarter of 2009, driven by the company's leading recombinant human erythropoietin injection EPIAO, the only approved EPO drug in China

3SBio Files For Approval For Interleukin-2 NuLeusin

SHANGHAI - 3SBio filed an application for the approval of NuLeusin with China's State FDA Nov. 10, hoping to make it the first product of its kind on the Chinese market, the Shenyang-based company announced

UsernamePublicRestriction

Register

SC070950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel